LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Kodu・Aktsiate loetelu・Johnson and Johnson

Johnson and Johnson

Suletud

Sektor Tervishoid

164.37 -0.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

164.14

Max

164.71

Põhinäitajad
By Trading Economics
Sissetulek	1.4B 4.7B
Müük	1.1B 22B
P/E Sektori keskmine	21.72 103.001
Aktsiakasum	2.82
Kasumimarginaal	20.873
Töötajad	131,900
EBITDA	2.1B 7.8B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+4.92 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	15. okt 2024
Järgmine dividendimakse kuupäev	10. sept 2024
Järgmine aktsia dividendi kuupäev (ex-date)	18. nov 2024

Turustatistika
By TradingEconomics
Turukapital	400B
Eelmine avamishind	164.66
Eelmine sulgemishind	164.37

Uudiste sentiment

By Acuity

55%

45%

293 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

164.13 / 164.61 Toetus ja vastupanu

Johnson and Johnson Graafik

Seotud uudised

20. aug 2024, 12:16 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600 Million

20. aug 2024, 11:43 UTC

Peamised uudised

Johnson & Johnson's Rybrevant, Lazcluze Combo Gets FDA Approval for Type of Advanced Lung Cancer

17. juuli 2024, 14:14 UTC

Tulu

Trending: Johnson & Johnson Beats 2Q Sales Guidance

4. sept 2024, 23:20 UTC

Peamised uudised

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

23. aug 2024, 20:54 UTC

Peamised uudised

J&J Takes Aim at Hospital Drug-Discount Program -- Update

23. aug 2024, 18:09 UTC

Peamised uudised

J&J Takes Aim At Hospital Drug-Discount Program -- WSJ

20. aug 2024, 12:41 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion -- Barrons.com

20. aug 2024, 12:01 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600M

20. aug 2024, 11:55 UTC

Omandamised, ülevõtmised, äriostud

J&J To Acquire V-Wave For Up To $1.7 Billion In Play For Heart Failure Device -- MarketWatch

20. aug 2024, 11:31 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Expects the Transaction to Dilute Adjusted EPS by 24c in 2024 and 6c in 2025 >JNJ

20. aug 2024, 11:31 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Transaction Is Expected to Close Before the End of 2024 >JNJ

20. aug 2024, 11:31 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Join Johnson & Johnson as Part of Johnson & Johnson MedTech >JNJ

20. aug 2024, 11:31 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Acquire V-Wave for an Upfront Payment of $600M With the Potential for Additional Regulatory and Comml Milestone Payments Up to $1.1B >JNJ

20. aug 2024, 11:30 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson To Acquire V-Wave >JNJ

20. aug 2024, 11:12 UTC

Peamised uudised

Johnson & Johnson Wins First FDA Approval For Chemotherapy-Free Lung Cancer Treatment -- MarketWatch

12. aug 2024, 14:30 UTC

Omandamised, ülevõtmised, äriostud

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12. aug 2024, 09:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Big Drugmakers Are Clinching Smaller Deals -- WSJ

29. juuli 2024, 10:30 UTC

Peamised uudised

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

17. juuli 2024, 11:24 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17. juuli 2024, 10:43 UTC

Tulu

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson: 2Q Innovative Medicine Worldwide Operational Sales, Excluding Covid Vaccine, Grew 8.8% >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson Updating 2024 Guidance to Reflect Improved Performance and Impact for Recent Acquisitions of Shockwave Medical, Proteologix and NM26 Bispecific Antibody >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson Raises 2024 Operational Sales View to $89.2B-$89.6B Vs Prior View $88.7B-$89.1B >JNJ

17. juuli 2024, 10:20 UTC

Tulu

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

4.92% tõus

12 kuu keskmine prognoos

Keskmine 172.46 USD 4.92%

Kõrge 215 USD

Madal 150 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Johnson and Johnson aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

164.13 / 164.61Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

293 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.